News | June 08, 2009

Study Finds 3D Echo is a Stronger Outcome Predictor Than 2D

June 9, 2009 – Physicians can better predict potentially life-threatening cardiac events with real-time, three-dimensional echocardiography technology, according to a study released at the 20th Annual Scientific Sessions of the American Society of Echocardiography (ASE) in Washington, D.C.

The study concluded that 3D measurements could help guide management decisions on how to best treat the patient and better predict the patient’s chance of survival.

Left ventricular end systolic volume measured by 2D echocardiography is an important correlate of survival. Researchers sought to determine whether 3D echo was more predictive of outcome than 2D echo. The study included 535 patients referred for left ventricle assessment. Patients were assessed with 2D and 3D echocardiography.

Over four to five years, cardiac admission, incident heart failure, atrial fibrillation and all-cause mortality information was obtained in 461 of 504 patients with images suitable for measurement. The results showed 48 cardiac events (10 percent) including 34 deaths. Larger left ventricular end-systolic volume and lower ejection fraction were associated with worse outcome.

The addition of 2D echo end-systolic volume increased the association of clinical variables—renal disease, left ventricular impairment and age – with outcome, but 3D echo end-systolic volume increased the strength of association. Similarly, the incremental value of 2D echo ejection fraction was exceeded by 3D echo ejection fraction.

The study was conducted by Carly Jenkins, Tony Stanton and Thomas H. Marwick at University of Queensland in Woolloongabba, Australia.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now